Protagonist Therapeutics, Inc. (PTGX)
PTGX Stock Price Chart
Explore Protagonist Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PTGX price movements and trends.
PTGX Company Profile
Discover essential business fundamentals and corporate details for Protagonist Therapeutics, Inc. (PTGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Aug 2016
Employees
124.00
Website
https://www.protagonist-inc.comCEO
Dinesh V. Patel
Description
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PTGX Financial Timeline
Browse a chronological timeline of Protagonist Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $2.11, while revenue estimate is $190.99m.
Earnings released on 5 May 2026
EPS came in at $0.05 surpassing the estimated -$0.65 by +107.69%, while revenue for the quarter reached $56.37m , beating expectations by +381.69%.
Earnings released on 25 Feb 2026
EPS came in at -$0.69 falling short of the estimated -$0.53 by -30.19%, while revenue for the quarter reached $7.44m , missing expectations by -14.92%.
Earnings released on 6 Nov 2025
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%, while revenue for the quarter reached $4.71m , missing expectations by -68.41%.
Earnings released on 6 Aug 2025
EPS came in at -$0.55 falling short of the estimated -$0.53 by -3.77%, while revenue for the quarter reached $5.55m , missing expectations by -34.20%.
Earnings released on 6 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.50 by +62.00%, while revenue for the quarter reached $28.32m , beating expectations by +332.01%.
Earnings released on 21 Feb 2025
EPS came in at $1.98 surpassing the estimated $0.06 by +3.20k%, while revenue for the quarter reached $170.64m , beating expectations by +110.63%.
Earnings released on 7 Nov 2024
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $4.68m , missing expectations by -87.95%.
Earnings released on 6 Aug 2024
EPS came in at -$0.50 matching the estimated -$0.50, while revenue for the quarter reached $4.17m , missing expectations by -47.91%.
Earnings released on 7 May 2024
EPS came in at $3.26 surpassing the estimated $1.19 by +173.95%, while revenue for the quarter reached $254.95m , beating expectations by +112.46%.
Earnings released on 27 Feb 2024
EPS came in at $0.44 surpassing the estimated $0.03 by +1.43k%, while revenue for the quarter reached $60.00m , beating expectations by +50.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.58 surpassing the estimated -$0.68 by +14.71%.
Earnings released on 3 Aug 2023
EPS came in at -$0.68 falling short of the estimated -$0.65 by -4.62%.
Earnings released on 4 May 2023
EPS came in at -$0.67 surpassing the estimated -$0.69 by +2.90%.
Earnings released on 15 Mar 2023
EPS came in at -$0.69 falling short of the estimated -$0.67 by -2.99%.
Earnings released on 8 Nov 2022
EPS came in at -$0.64 surpassing the estimated -$0.94 by +31.91%.
Earnings released on 4 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$0.99 by +15.15%, while revenue for the quarter reached $859.00k , beating expectations by +86.74%.
Earnings released on 4 May 2022
EPS came in at -$0.43 surpassing the estimated -$0.67 by +35.82%, while revenue for the quarter reached $25.72m , beating expectations by +21.43%.
Earnings released on 28 Feb 2022
EPS came in at -$0.77 surpassing the estimated -$0.79 by +2.53%, while revenue for the quarter reached $8.62m , beating expectations by +69.91%.
Earnings released on 3 Nov 2021
EPS came in at -$0.70 falling short of the estimated -$0.67 by -4.48%, while revenue for the quarter reached $10.29m , beating expectations by +406.70%.
Earnings released on 4 Aug 2021
EPS came in at -$0.69 falling short of the estimated -$0.62 by -11.29%, while revenue for the quarter reached $2.27m , missing expectations by -56.19%.
PTGX Stock Performance
Access detailed PTGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
